Targeting the IDO1 pathway in cancer: from bench to bedside

High IDO-1 expression in tumor endothelial cells is associated with response to immunotherapy in metastatic renal cell carcinoma

(2018) Andreas Seeber et al.   CANCER SCIENCE

IDO1 Inhibition Synergizes with Radiation and PD-1 Blockade to Durably Increase Survival Against Advanced Glioblastoma

(2018) Erik Ladomersky et al.   CLINICAL CANCER RESEARCH

Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies

(2018) Shetal A. Patel et al.   IMMUNITY

Cancer immunotherapy beyond immune checkpoint inhibitors

(2018) Julian A. Marin-Acevedo et al.   Journal of Hematology & Oncology

Gut microbiome modulates efficacy of immune checkpoint inhibitors

(2018) Ming Yi et al.   Journal of Hematology & Oncology

Next generation of immune checkpoint therapy in cancer: new developments and challenges

(2018) Julian A. Marin-Acevedo et al.   Journal of Hematology & Oncology

miR-153 suppresses IDO1 expression and enhances CAR T cell immunotherapy

(2018) Qian Huang et al.   Journal of Hematology & Oncology

Microbiome: Gut microbiota sways response to cancer immunotherapy

(2018) Ashley York   NATURE REVIEWS MICROBIOLOGY

Targeting the IDO1/TDO2–KYN–AhR Pathway for Cancer Immunotherapy – Challenges and Opportunities

(2018) Jae Eun Cheong et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

The Pancreatic Cancer Microbiome Promotes Oncogenesis by Induction of Innate and Adaptive Immune Suppression

(2018) Smruti Pushalkar et al.   Cancer Discovery

Hypoxia enhances indoleamine 2,3-dioxygenase production in dendritic cells

(2018) Xiang Song et al.   Oncotarget

Impact of the Gut Microbiota on Intestinal Immunity Mediated by Tryptophan Metabolism

(2018) Jing Gao et al.   Frontiers in Cellular and Infection Microbiology

Antigen-Specific Antitumor Responses Induced by OX40 Agonist Are Enhanced by the IDO Inhibitor Indoximod

(2018) Zuzana Berrong et al.   Cancer Immunology Research

High Indoleamine 2,3-Dioxygenase Is Correlated With Microvessel Density and Worse Prognosis in Breast Cancer

(2018) Lijuan Wei et al.   Frontiers in Immunology

Expression of Indoleamine 2,3-Dioxygenase Induced by IFN-γ and TNF-α as Potential Biomarker of Prostate Cancer Progression

(2018) Irina Banzola et al.   Frontiers in Immunology

The Role of Indoleamine-2,3-Dioxygenase in Cancer Development, Diagnostics, and Therapy

(2018) Lilla Hornyák et al.   Frontiers in Immunology

Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas

(2018) Maud Toulmonde et al.   JAMA Oncology

A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)–only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer

(2017) Rebecca Kristeleit et al.   GYNECOLOGIC ONCOLOGY

Combinatorial antitumor effects of indoleamine 2,3-dioxygenase inhibitor NLG919 and paclitaxel in a murine B16-F10 melanoma model

(2017) Xiangjing Meng et al.   INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY

Clinical trials of CAR-T cells in China

(2017) Bingshan Liu et al.   Journal of Hematology & Oncology

Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy

(2017) Bingshan Liu et al.   Journal of Hematology & Oncology

Chimeric antigen receptors for adoptive T cell therapy in acute myeloid leukemia

(2017) Mingxue Fan et al.   Journal of Hematology & Oncology

Heme-containing enzymes and inhibitors for tryptophan metabolism

(2017) Daojing Yan et al.   Metallomics

Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients

(2017) V. Gopalakrishnan et al.   SCIENCE

Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors

(2017) Bertrand Routy et al.   SCIENCE

INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immuno-oncology

(2017) Eddy W. Yue et al.   ACS Medicinal Chemistry Letters

Constitutive IDO1 Expression in Human Tumors Is Driven by Cyclooxygenase-2 and Mediates Intrinsic Immune Resistance

(2017) Marc Hennequart et al.   Cancer Immunology Research

Determination of epacadostat, a novel IDO1 inhibitor in mouse plasma by LC-MS/MS and its application to a pharmacokinetic study in mice

(2016) Vinay Dhiman et al.   BIOMEDICAL CHROMATOGRAPHY

Abstract 4863: PF-06840003: a highly selective IDO-1 inhibitor that shows good in vivo efficacy in combination with immune checkpoint inhibitors

(2016) Joseph Tumang et al.   CANCER RESEARCH

Differential effects of the two amino acid sensing systems, the GCN2 kinase and the mTOR complex 1, on primary human alloreactive CD4+ T-cells

(2016) THEODOROS ELEFTHERIADIS et al.   INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE

Tolerogenic Phenotype of IFN-γ–Induced IDO+Dendritic Cells Is Maintained via an Autocrine IDO–Kynurenine/AhR–IDO Loop

(2016) Qingsheng Li et al.   JOURNAL OF IMMUNOLOGY

Combinatorial approach to cancer immunotherapy: strength in numbers

(2016) Anna E. Vilgelm et al.   JOURNAL OF LEUKOCYTE BIOLOGY

IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance

(2016) David H. Munn et al.   TRENDS IN IMMUNOLOGY

The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells

(2016) Caroline Jochems et al.   Oncotarget

A phase I study of indoximod in patients with advanced malignancies

(2016) Hatem H. Soliman et al.   Oncotarget

Hepatic carcinoma-associated fibroblasts induce IDO-producing regulatory dendritic cells through IL-6-mediated STAT3 activation

(2016) J-t Cheng et al.   Oncogenesis

Tolerogenic IDO+ Dendritic Cells Are Induced by PD-1-Expressing Mast Cells

(2016) Cecilia Pessoa Rodrigues et al.   Frontiers in Immunology

IDO1 is an Integral Mediator of Inflammatory Neovascularization

(2016) Arpita Mondal et al.   EBioMedicine

Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs

(2015) Soranobu Ninomiya et al.   BLOOD

Role of indoleamine 2,3-dioxygenase in health and disease

(2015) Amanda W.S. Yeung et al.   CLINICAL SCIENCE

Challenges and Opportunities in the Discovery of New Therapeutics Targeting the Kynurenine Pathway

(2015) Amy B. Dounay et al.   JOURNAL OF MEDICINAL CHEMISTRY

Challenges in the Discovery of Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors

(2015) Ute F. Röhrig et al.   JOURNAL OF MEDICINAL CHEMISTRY

The amino acid sensor GCN2 inhibits inflammatory responses to apoptotic cells promoting tolerance and suppressing systemic autoimmunity

(2015) Buvana Ravishankar et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Regulation of T cells by mTOR: the known knowns and the known unknowns

(2015) Kristen N. Pollizzi et al.   TRENDS IN IMMUNOLOGY

Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner

(2015) Rikke B. Holmgaard et al.   Cell Reports

The Coevolution of IDO1 and AhR in the Emergence of Regulatory T-Cells in Mammals

(2015) Ursula Grohmann et al.   Frontiers in Immunology

Expression profile of the human IDO1 protein, a cancer drug target involved in tumoral immune resistance

(2015) Nathalie Vigneron et al.   OncoImmunology

Indoleamine 2,3-dioxygenase vaccination

(2015) Mads Hald Andersen et al.   OncoImmunology

The PTEN pathway in Tregs is a critical driver of the suppressive tumor microenvironment

(2015) M. D. Sharma et al.   Science Advances

Abstract 5023: Synergistic antitumor effects of combinatorial immune checkpoint inhibition with anti-PD-1/PD-L antibodies and the IDO pathway inhibitors NLG-919 and indoximod in the context of active immunotherapy

(2015) Mario R. Mautino et al.   CANCER RESEARCH

A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors

(2015) Hatem H. Soliman et al.   Oncotarget

Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer

(2014) George C. Prendergast et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Abstract 491: NLG919, a novel indoleamine-2,3-dioxygenase (IDO)-pathway inhibitor drug candidate for cancer therapy.

(2014) Mario R. Mautino et al.   CANCER RESEARCH

Mesenchymal Stem Cells Use IDO to Regulate Immunity in Tumor Microenvironment

(2014) W. Ling et al.   CANCER RESEARCH

Noncanonical NF-κB Activation Mediates STAT3-Stimulated IDO Upregulation in Myeloid-Derived Suppressor Cells in Breast Cancer

(2014) Jinpu Yu et al.   JOURNAL OF IMMUNOLOGY

Long-lasting Disease Stabilization in the Absence of Toxicity in Metastatic Lung Cancer Patients Vaccinated with an Epitope Derived from Indoleamine 2,3 Dioxygenase

(2013) T. Z. Iversen et al.   CLINICAL CANCER RESEARCH

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4

(2013) Rikke B. Holmgaard et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Myeloid-Derived Suppressor Cells Suppress Antitumor Immune Responses through IDO Expression and Correlate with Lymph Node Metastasis in Patients with Breast Cancer

(2013) J. Yu et al.   JOURNAL OF IMMUNOLOGY

IDO Expression in Brain Tumors Increases the Recruitment of Regulatory T Cells and Negatively Impacts Survival

(2012) D. A. Wainwright et al.   CLINICAL CANCER RESEARCH

Tumor suppressor TSC1 is critical for T-cell anergy

(2012) D.-L. Xie et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Indoleamine 2,3 dioxygenase and metabolic control of immune responses

(2012) David H. Munn et al.   TRENDS IN IMMUNOLOGY

IDO Is a Nodal Pathogenic Driver of Lung Cancer and Metastasis Development

(2012) Courtney Smith et al.   Cancer Discovery

IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan

(2012) Richard Metz et al.   OncoImmunology

Clinicopathological significance of indoleamine 2,3-dioxygenase 1 expression in colorectal cancer

(2011) L Ferdinande et al.   BRITISH JOURNAL OF CANCER

Indoleamine 2,3-Dioxygenase Expression in Human Cancers: Clinical and Immunologic Perspectives

(2011) J. Godin-Ethier et al.   CLINICAL CANCER RESEARCH

An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor

(2011) Christiane A. Opitz et al.   NATURE

Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells

(2011) Maria T Pallotta et al.   NATURE IMMUNOLOGY

Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido

(2011) Vinod P Balachandran et al.   NATURE MEDICINE

Indoleamine 2,3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells

(2009) D. J. Chung et al.   BLOOD

Aryl hydrocarbon receptor signaling mediates expression of indoleamine 2,3-dioxygenase

(2008) Christoph F.A. Vogel et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase

(2008) A. J. Muller et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA